Where does Cognos Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cognos Therapeutics, Inc. ranks #34,798 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cognos Therapeutics, Inc. hold?

Cognos Therapeutics, Inc. holds 7 US utility patents granted between 2020 and 2025, spanning 6 technology areas.

What is Cognos Therapeutics, Inc.'s Innovation Score?

Cognos Therapeutics, Inc. has an Innovation Score of 43.1 out of 100 (top 29% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Cognos Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Cognos Therapeutics, Inc..

What does claim depth mean for Cognos Therapeutics, Inc.'s patents?

Cognos Therapeutics, Inc.'s patents average 12.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cognos Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Cognos Therapeutics, Inc.

Q: What technology areas does Cognos Therapeutics, Inc. focus on?

Cognos Therapeutics, Inc.'s top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 7 patents, ranking #969 of 3,490 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 7 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cognos ranks #34,798 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 6 technology areas.

#34,798
of 49,997 US assignees by volume: Top 29%
by Innovation Score (43.1/100): 12.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R34798 · US Corporation #34,798 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 7 grants
MID-PACK #34,798/49,997
PHOTO-FINISH CMC Biologics A/S
CPC-NARROW A61M · 6 areas
INNOV-PAR 43.1/100
CLAIMS-RICH 12.1 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: CMC Biologics A/S (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cognos’s 43.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (17%) Velocity 20.0 pts (46%) Breadth 8.7 pts (20%) Claim depth 7.3 pts (17%)

Qualcomm Incorporated · highest

85
Cognos Therapeutics · this assignee

43
3D Lighting… · lowest

7

What this shows Cognos's Innovation Score is 43.1/100 (top 29% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cognos?

Each dot is one of Cognos’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cognos’s own 12.1 claims/patent is at or below the 13.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Cognos vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cognos's grants concentrate

Cognos Therapeutics, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2020. By volume, Cognos sits between CMC Biologics A/S and Color Health, Inc..

Cognos's three-year grant acceleration

Cognos Therapeutics, Inc. shows 5 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

CMC Biologics A/S

7
Cnpc Chuanqing Dr…

7
-tech Development

7
Codesys Holding

7
Cold Chain

7
Coldway

7
Coleman Cable

7
Color Health

7
Cognos Therapeuti… ◀

7

What this shows Cognos holds 7 patents at rank #34,704, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cognos

By rank, the assignees closest to #34,704 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Cognos's primary technology class.

Cognos's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 29% higher than 71% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Cognos Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	14.3%
2022	1	14.3%
2024	4	57.1%
2025partial year	1	14.3%

Which technologies does Cognos Therapeutics, Inc. patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 7

A61B - DIAGNOSIS; SURGERY; Identification 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C07K - Peptides 1

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cognos Therapeutics, Inc.'s patent record in context - here's where to go next.

Cognos Therapeutics, Inc.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 100% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #34,798 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cognos Therapeutics, Inc. against CMC Biologics A/S, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.